Jun 12, 2009
Women who undergo breast-conserving surgery for ductal carcinoma in situ (DCIS) often do not receive long-term surveillance mammography, according to a study published online May 11 in the Journal of Clinical Oncology.
 |
Sep 1, 2008
In most obese women, neither Ocs nor current screening methods are cost-effective endometrial cancer prevention strategies.
|
Ob/gyns now have more options than ever to ward off adhesions and achieve hemostasis.
Apr 15, 2008
By:Matthew W. Guile, MD, Robert E. Bristow, MD
Adhesion barriers and controlling excess bleeding during pelvic surgery are easier than ever—thanks to biotechnology advances.
|
Endometrial cancer survivors are more likely to be obese and to die from co-existing illnesses. Here are at least five ways gynecologists can help them live longer—with a better quality of life.
Nov 1, 2007
By:Amanda Nickles Fader, MD, Heidi E. Gibbons, MS, Vivian E. von Gruenigen, MD
Endometrial cancer survivors are more likely to be obese and to die from co-existing illnesses. Here are at least five ways gynecologists can help them live longer—with a better quality of life.
|
 | A laparoscopic procedure is an option for many women with endometrial cancer. Here, two expert gynecologic oncologists tell you what the surgery involves and how to select patients for referral.
Feb 1, 2007
By:Pedro T. Ramirez, MD, Brian M. Slomovitz, MD
A laparoscopic procedure is an option for many women with endometrial cancer. Here, two expert gynecologic oncologists tell you what the surgery involves and how to select patients for referral.
|
Nov 1, 2006
By:Michael L. McDaniel, MD, Andrew Berchuck, MD
How many times has a patient said, "Oh, by the way, doctor..." just as you're leaving the exam room? This column will help you quickly triage those seemingly offhand yet clinically significant encounters.
|
Will biological warfare revolutionize the battle against gynecologic cancers? Two experts share the latest molecular tactics using "special" agents. Lethal weapons like Herceptin can throw up some roadblocks, even when they can't always destroy a tumor.
Oct 1, 2006
By:Angeles Alvarez Secord, MD, Andrew Berchuck, MD
Will biological warfare revolutionize the battle against gynecologic cancers? Two experts share the latest molecular tactics using "special" agents. Lethal weapons like Herceptin can throw up some roadblocks, even when they can't always destroy a tumor.
|
Though most of these common tumors are benign, 0.5% of patients undergoing hysterectomy for presumed fibroids will be found to have a leiomyosarcoma, which usually kills within 5 years if it spreads outside the uterus. And five patients' leiomyosarcomas weren't diagnosed until after UAE.
Aug 1, 2006
By:Robert L. Giuntoli, II, MD, Robert E. Bristow, MD
Though most of these common tumors are benign, 0.5% of patients undergoing hysterectomy for presumed fibroids will be found to have a leiomyosarcoma, which usually kills within 5 years if it spreads outside the uterus. And five patients' leiomyosarcomas weren't diagnosed until after UAE.
|
| 
